IRIS
VIGNA, ERNESTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.672
NA - Nord America 1.707
EU - Europa 882
SA - Sud America 753
AF - Africa 114
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 6.136
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.578
SG - Singapore 970
BR - Brasile 560
CN - Cina 524
VN - Vietnam 467
IT - Italia 390
HK - Hong Kong 195
BD - Bangladesh 134
FR - Francia 103
DE - Germania 92
AR - Argentina 64
KR - Corea 64
FI - Finlandia 57
MX - Messico 51
CA - Canada 44
IN - India 44
GB - Regno Unito 42
IQ - Iraq 42
ZA - Sudafrica 32
EC - Ecuador 31
PK - Pakistan 31
RU - Federazione Russa 30
UA - Ucraina 30
NL - Olanda 29
CO - Colombia 27
ID - Indonesia 26
AT - Austria 24
UZ - Uzbekistan 20
TR - Turchia 19
PH - Filippine 17
CL - Cile 15
VE - Venezuela 15
ES - Italia 14
JP - Giappone 14
PY - Paraguay 14
DZ - Algeria 13
MA - Marocco 13
PL - Polonia 13
SA - Arabia Saudita 13
KE - Kenya 11
UY - Uruguay 11
MY - Malesia 10
TN - Tunisia 10
ET - Etiopia 9
JO - Giordania 9
AE - Emirati Arabi Uniti 8
EG - Egitto 8
IL - Israele 8
PE - Perù 8
BO - Bolivia 7
KG - Kirghizistan 7
LB - Libano 7
PA - Panama 7
CR - Costa Rica 6
AL - Albania 5
AZ - Azerbaigian 5
BA - Bosnia-Erzegovina 5
CZ - Repubblica Ceca 5
NP - Nepal 5
OM - Oman 5
PS - Palestinian Territory 5
SE - Svezia 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
RO - Romania 4
SN - Senegal 4
AU - Australia 3
CH - Svizzera 3
GT - Guatemala 3
JM - Giamaica 3
KH - Cambogia 3
KZ - Kazakistan 3
NG - Nigeria 3
NI - Nicaragua 3
QA - Qatar 3
RS - Serbia 3
SC - Seychelles 3
SK - Slovacchia (Repubblica Slovacca) 3
BE - Belgio 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
DK - Danimarca 2
KW - Kuwait 2
LT - Lituania 2
LY - Libia 2
MK - Macedonia 2
NO - Norvegia 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TW - Taiwan 2
AM - Armenia 1
AQ - Antartide 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
GA - Gabon 1
GE - Georgia 1
Totale 6.117
Salva come PNG Salva come JPEG
Città #
Singapore 426
San Jose 263
Dallas 231
Hong Kong 193
Ashburn 183
Ho Chi Minh City 163
Florence 137
Boardman 135
Council Bluffs 120
Hefei 103
Beijing 101
Hanoi 98
Seoul 63
Lauterbourg 62
São Paulo 56
Shanghai 48
Los Angeles 43
New York 42
Munich 41
Helsinki 40
Santa Clara 29
Rio de Janeiro 24
Da Nang 23
Milan 23
Haiphong 22
Sesto Fiorentino 22
Noto 20
Montreal 19
Rome 19
Guangzhou 18
Baghdad 17
Tashkent 17
Quito 16
Brooklyn 15
Brasília 13
Mexico City 13
Naples 13
The Dalles 13
Vienna 13
Washington 13
Amsterdam 11
Catania 11
Chicago 11
Hillsboro 11
Johannesburg 11
Lahore 11
Orem 11
Tokyo 11
Buffalo 10
Guayaquil 10
Nairobi 10
Addis Ababa 9
Amman 9
Biên Hòa 9
Frankfurt am Main 9
Ninh Bình 9
Phoenix 9
Thái Nguyên 9
Turku 9
Wuhan 9
Atlanta 8
Bari 8
Belo Horizonte 8
Charlotte 8
Chennai 8
Dhaka 8
Karachi 8
Lappeenranta 8
London 8
Medellín 8
Montevideo 8
Warsaw 8
Campinas 7
Can Tho 7
Caracas 7
Erbil 7
Fortaleza 7
Hangzhou 7
Kyiv 7
Naaldwijk 7
Nuremberg 7
Ogden 7
Ribeirão Preto 7
San Francisco 7
Bishkek 6
Bogotá 6
Cape Town 6
Curitiba 6
Portland 6
Santiago 6
Boston 5
Bragança Paulista 5
Denver 5
Duhok 5
Feira de Santana 5
Hải Dương 5
Kuala Lumpur 5
Manaus 5
Miami 5
Recife 5
Totale 3.375
Salva come PNG Salva come JPEG
Nome #
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 176
Vaccination in Multiple Myeloma: Challenges and Strategies 132
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 128
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 126
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 124
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 123
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 117
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 116
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 116
Momelotinib in myelofibrosis 115
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 112
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 110
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 110
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 109
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 108
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 108
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 108
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 107
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 105
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 103
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 103
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 102
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 100
The role of corticosteroids in the current treatment paradigm for myelofibrosis 99
Belantamab mafodotin in multiple myeloma 98
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 93
Iron chelation therapy 92
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 91
Teclistamab-cqyv in multiple myeloma 91
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 90
Selinexor in multiple myeloma 89
Acalabrutinib in chronic lymphocytic leukemia 89
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 87
Elotuzumab in multiple myeloma 87
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 84
Cerebral pheohyphomycosis due to curvularia species 83
Myelodysplastic syndromes with ring sideroblasts 83
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 82
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 82
Ivosidenib in acute myeloid leukemia 81
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 80
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 80
Avatrombopag for the Treatment of Immune Thrombocytopenia 78
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 78
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 75
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 73
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 71
Glasdegib for the treatment of acute myeloid leukemia 69
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients 69
Zanubrutinib for the treatment of chronic lymphocytic leukemia 69
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs 68
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 67
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 65
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 65
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 64
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions 62
Mosunetuzumab for the treatment of follicular lymphoma 60
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 59
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 55
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents 51
Performance of the Bova score in predicting short-term all-cause mortality in patients with pulmonary embolism and normal blood pressure. A systematic review and meta-analysis 49
Extracellular vesicles in multiple myeloma-bone marrow niche crosstalk: from cellular dialogue to clinical perspectives 48
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 48
Isatuximab in multiple myeloma 48
Venetoclax in acute myeloid leukemia 48
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 44
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 41
Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization 35
Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia 33
Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy 28
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 28
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care? 26
Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies 25
Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches 24
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort 22
Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy 20
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies 18
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction 17
Targeting the Menin– KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation 15
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials 15
Reshaping multiple myeloma treatment: recent breakthroughs 14
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration 14
Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions 13
Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs 12
Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM 11
Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 11
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives 7
What Does It Really Mean to Say That a Patient With a Hematologic Malignancy Is “Cured”? 4
Regional Standardization of CLL Management: Results of a Delphi Consensus Process 4
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies 4
First‐Line Treatment of IGHV ‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens 2
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management 2
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort 1
To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy 1
The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities 1
Gut Microbiota and Acute Myeloid Leukemia: State of the Art, Clinical Signals, and Translational Opportunities 1
Totale 6.251
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.725
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.725
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228 0 2 0 0 2 0 0 1 0 0 1 2
2022/202375 2 0 0 2 1 1 32 2 4 5 20 6
2023/2024530 10 17 105 84 49 64 24 17 17 8 19 116
2024/20251.200 45 99 33 62 59 45 24 61 178 124 123 347
2025/20264.430 424 237 407 305 694 326 484 226 366 432 267 262
Totale 6.251